RTA 901

Drug Profile

RTA 901

Alternative Names: RTA-901

Latest Information Update: 28 Jan 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Kansas
  • Developer Reata Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action HSP70 heat-shock protein modulators; HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Diabetic neuropathies

Most Recent Events

  • 10 Jan 2017 Phase-I clinical trials in Diabetic neuropathies (In volunteers) in USA (PO) (NCT02666963)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top